7 results
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
and pulmonary rehabilitation, with increased intensity of therapy guided by disease severity. Surgical options include lung volume reduction surgery and lung … , have increased in frequency, intensity, and sophistication. These threats pose a risk to the security of our and our collaborators’, CROs’, service
F-1/A
MREO
Mereo Biopharma Group Plc
12 Mar 20
Registration statement (foreign) (amended)
5:15pm
rehabilitation, with increased intensity of therapy guided by disease severity. Surgical options include lung volume reduction surgery and lung … reported as severe but most of the headaches were mild in intensity. Independent safety review committees evaluated this data and recommended
F-1/A
ukgldov2 nm2
6 Mar 20
Registration statement (foreign) (amended)
5:32pm
20-F
ole585e6ckj04
29 Apr 19
Annual report (foreign)
4:59pm
- Prev
- 1
- Next